Medexus Pharmaceuticals (TSE:MDP) Stock Rating Upgraded by Raymond James

Medexus Pharmaceuticals (TSE:MDP) was upgraded by investment analysts at Raymond James from an “outperform” rating to a “strong-buy” rating in a research note issued to investors on Wednesday,BayStreet.CA reports. The firm presently has a C$4.00 price objective on the stock. Raymond James’ price objective would suggest a potential upside of 11.42% from the company’s current price.

Other equities analysts also recently issued research reports about the company. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Monday, December 23rd. Leede Financial set a C$8.25 target price on Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research note on Monday, September 30th. Two research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Strong Buy” and an average price target of C$5.25.

Medexus Pharmaceuticals Price Performance

MDP traded up C$0.13 during trading on Wednesday, reaching C$3.59. 44,051 shares of the stock traded hands, compared to its average volume of 56,940. The stock has a market cap of C$88.06 million, a price-to-earnings ratio of 71.80 and a beta of 1.96. The stock’s 50-day simple moving average is C$2.72 and its two-hundred day simple moving average is C$2.50. Medexus Pharmaceuticals has a fifty-two week low of C$1.47 and a fifty-two week high of C$3.59.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.